Bortrac 2mg Injection

Bortrac 2mg Injection is given by a doctor or trained nurse under strict medical supervision. It is not self-administerable. The dosage and duration of the treatment are determined by the doctor based on the patient's health condition.

Bortrac 2mg Injection is an anticancer medicine that belongs to the class of proteasome inhibitors. It works by blocking or slowing down the breakdown of protein (26S proteasome) in cells. It leads to the accumulation of protein in cancer cells, which ultimately causes cell death.

It is not advisable to miss any dose of Bortrac 2 but in case you miss a dose, consult your doctor immediately.

At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.

Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.

Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.


We currently ship to:

Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!

1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215331s000lbl.pdf
2. Roccaro, A. M., Vacca, A., & Ribatti, D. (2006). Bortezomib in the treatment of cancer. Recent patents on anti-cancer drug discovery, 1(3), 397-403- https://pubmed.ncbi.nlm.nih.gov/18221049/
3. Kouroukis, T. C., Baldassarre, F. G., Haynes, A. E., Imrie, K., Reece, D. E., & Cheung, M. C. (2014). Bortezomib in multiple myeloma: systematic review and clinical considerations. Current oncology, 21(4), e573 - https://pubmed.ncbi.nlm.nih.gov/25089109/
4. Mujtaba, T., & Dou, Q. P. (2011). Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discovery medicine, 12(67), 471.
5. Jackson, G., Einsele, H., Moreau, P., & San Miguel, J. (2005). Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies. Cancer treatment reviews, 31(8), 591-602 - https://pubmed.ncbi.nlm.nih.gov/16298074/